Surrogate decision making of chemotherapy consent: do we really provide informed consent of chemotherapy for patients?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Despite increased demand for cancer patient’s to make their own decisions based on an adequate understanding of what is involved in chemotherapy, the primary signing agent and the reasons for surrogate signing have not been appropriately evaluated. Methods: The ethics committee of the palliative medicine subgroup of the Korean Cancer Study Group designed this study and solid cancer patients to whom chemotherapy was offered, from seven institutions, were evaluated. The details relating to surrogate’s signing of chemotherapy consent were evaluated. Then, we analyzed the factors associated with surrogate’s signing according to patient’s demographics and characteristics related to chemotherapy consent. Results: Surrogate’s signing was noted for 20.7% (84/405) of patient and over half of surrogate signings were performed by the patients’ son or daughter (60.7%). Two main reasons for surrogate signing were patient’s incapacity (34.5%) and taking over authorization from patients (33.3%). The factors associated with more frequent surrogate’s signing were absence of spouse, lower education level, outpatient, and when residents played a role as a principle provider of chemotherapy consent. Conclusions: This study suggests the lack of patients’ own decision making for chemotherapy in some situations. This ethical dilemma must be considered for adequately informed decision making for chemotherapy while ensuring the patients’ autonomy is maintained.
Abstract
Background/Aims: Despite increased demand for cancer patient’s to make their own decisions based on an adequate understanding of what is involved in chemotherapy, the primary signing agent and the reasons for surrogate signing have not been appropriately evaluated. Methods: The ethics committee of the palliative medicine subgroup of the Korean Cancer Study Group designed this study and solid cancer patients to whom chemotherapy was offered, from seven institutions, were evaluated. The details relating to surrogate’s signing of chemotherapy consent were evaluated. Then, we analyzed the factors associated with surrogate’s signing according to patient’s demographics and characteristics related to chemotherapy consent. Results: Surrogate’s signing was noted for 20.7% (84/405) of patient and over half of surrogate signings were performed by the patients’ son or daughter (60.7%). Two main reasons for surrogate signing were patient’s incapacity (34.5%) and taking over authorization from patients (33.3%). The factors associated with more frequent surrogate’s signing were absence of spouse, lower education level, outpatient, and when residents played a role as a principle provider of chemotherapy consent. Conclusions: This study suggests the lack of patients’ own decision making for chemotherapy in some situations. This ethical dilemma must be considered for adequately informed decision making for chemotherapy while ensuring the patients’ autonomy is maintained.
참고문헌 (20)
- Sharpe G, "Consent to medical treatment", Can Med Assoc J, 117, pp.692~694 (1977)
- Schachter M, "Informed consent revisited : a doctrine in the service of cancer care", Oncologist, 13, pp.1109~1113 (2008)
- Mazur DJ, "What should patients be told prior to a medical procedure? Ethical and legal perspectives on medical informed consent", Am J Med, 81, pp.1051~1054 (1986)
- "Informed consent for chemotherapy administration" (2018)[URL]
- "Chemotherapy consent form of Korean Academy of Medical Sciences" (2017)[URL]
- "Patient’s autonomy" (2012)[URL]
- Degner LF, "Information needs and decisional preferences in women with breast cancer", JAMA, 277, pp.1485~1492 (1997)
- Sarradon-Eck A, "The surrogate : partner in the shared decision-making", Bull Cancer, 103, pp.632~642 (2016)
- Lee HR, "Making an informed decision of Korean cancer patients : the discrepancy between a patient's recall of information and the information needed for acquisition of radiotherapy informed consent", Support Care Cancer, 26, pp.297~303 (2018)
- Lee JK, "Surrogate decision-making in Korean patients with advanced cancer : a longitudinal study", Support Care Cancer, 21, pp.183~190 (2013)
- Kim DY, "Do-not-resuscitate orders for terminal patients with cancer in teaching hospitals of Korea", J Palliat Med, 10, pp.1153~1158 (2007)
- Hauke D, "The role of relatives in decisions concerning life-prolonging treatment in patients with end-stage malignant disorders: informants, advocates or surrogate decision-makers?", Ann Oncol, 22, pp.2667~2674 (2011)
- Liu TW, "Terminally ill Taiwanese cancer patients' and family caregivers' agreement on patterns of life-sustaining treatment preferences is poor to fair and declines over a decade : results from two independent cross-sectional studies", J Pain Symptom Manage, 54, pp.35~45 (2017)
- Glezer A, "Documentation of decision-making capacity, informed consent, and health care proxies : a study of surrogate consent", Psychosomatics, 52, pp.521~529 (2011)
- Appelbaum PS, "Clinical practice. Assessment of patients'competence to consent to treatment", N Engl J Med, 357, pp.1834~1840 (2007)
- "Power of attorney" (2018)[URL]
- Sand K, "Lung cancer patients' perceptions of informed consent documents", Patient Educ Couns, 73, pp.313~317 (2008)
- 김도연, "Survey of Medical Oncology Status in Korea (SOMOS-K): A National Survey of Medical Oncologists in the Korean Association for Clinical Oncology (KACO)", Cancer Research and Treatment, 49(3), pp.588~594 (2017), 대한암학회
- Mack JW, "Patient beliefs that chemotherapy may be curative and care received at the end of life among patients with metastatic lung and colorectal cancer", Cancer, 121, pp.1891~1897 (2015)
- "Law for ‘patient’s making their own decisions toward life sustaining treatment" (1997)[URL]